<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bartonella infections in people with HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bartonella infections in people with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bartonella infections in people with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David H Spach, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roy M Gulick, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Bartonella</em> infections can cause serious morbidity and mortality in people with human immunodeficiency virus (HIV), particularly those with advanced immunosuppression. This topic will address <em>Bartonella</em> infections in people with HIV.</p><p>Detailed information regarding the microbiologic tests for <em>Bartonella</em> is found elsewhere. (See  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a>.)</p><p>Other aspects of <em>Bartonella</em> infection are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5530.html" rel="external">"Treatment of cat scratch disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2145.html" rel="external">"Endocarditis caused by Bartonella"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5517.html" rel="external">"Bartonella quintana infections: Clinical features, diagnosis, and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5516.html" rel="external">"South American bartonellosis: Oroya fever and verruga peruana"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5519.html" rel="external">"Basic biology of Bartonella species"</a>.)</p><p></p><p class="headingAnchor" id="H14119129"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Although more than 35 distinct species of <em>Bartonella</em> are officially recognized, only two <em>Bartonella</em> species cause a significant number of infections in individuals with HIV: <em>Bartonella henselae</em> and <em>Bartonella quintana</em> [<a href="#rid1">1-3</a>].</p><p>Among individuals with HIV and <em>Bartonella</em>-associated infections, <em>B. henselae</em> and <em>B. quintana </em>appear to have differing organ tropisms [<a href="#rid4">4</a>]. <em>B. henselae</em> predominantly causes cutaneous, lymph node, liver, and splenic lesions, whereas <em>B. quintana </em>most often causes cutaneous, subcutaneous, and bone infections. Either organism appears to be equally capable of causing cutaneous lesions.</p><p>Detailed information on the biology of <em>Bartonella</em> can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/5519.html" rel="external">"Basic biology of Bartonella species"</a>.)</p><p class="headingAnchor" id="H14119136"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H117081067"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>Primary routes of transmission for <em>Bartonella</em> vary by the species:</p><p class="bulletIndent1"><span class="glyph">●</span>People with HIV who have <em>B. henselae</em> infection usually have a history of cat exposure [<a href="#rid4">4</a>]. The transmission of <em>B. henselae</em> to humans is usually via a scratch from a cat whose claws are contaminated with feces from <em>Bartonella</em>-infected fleas. More details regarding the transmission of <em>B. henselae</em> are found elsewhere. (See  <a class="medical medical_review" href="/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease"</a> and  <a class="medical medical_review" href="/d/html/5519.html" rel="external">"Basic biology of Bartonella species"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>B. quintana</em> infections predominantly occur in people who are homeless and acquire the infection from infected body lice [<a href="#rid4">4</a>]. Details regarding the transmission of <em>B. quintana</em> are found elsewhere. (See  <a class="medical medical_review" href="/d/html/5517.html" rel="external">"Bartonella quintana infections: Clinical features, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/5519.html" rel="external">"Basic biology of Bartonella species"</a>.)</p><p></p><p class="headingAnchor" id="H88095191"><span class="h2">Seroprevalence</span><span class="headingEndMark"> — </span>Although clinically symptomatic bartonellosis is relatively uncommon, seroepidemiologic studies have reported a high seroprevalence of antibodies against <em>Bartonella</em> among individuals with HIV [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A serologic study in Spain demonstrated elevated <em>B. henselae</em> titers (immunoglobulin [Ig]G ≥1:64) in a higher proportion of people with HIV than HIV-negative blood donors (9 of 52 [17 percent] versus 5 of 85 [5 percent], respectively) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A seroprevalence study in Greece found that 41 percent of people with HIV had positive IgG antibodies to <em>B. henselae</em> [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A serologic study in San Diego, California of 177 people with HIV who were enrolled in a longitudinal study of neurocognitive function found that 11 percent had positive serology for <em>B. henselae</em> [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H4170882257"><span class="h2">Prevalence of disease</span><span class="headingEndMark"> — </span>The prevalence of clinically evident <em>Bartonella</em> infections in people with HIV is relatively low. As an example, in one study from Germany, the prevalence of HIV-associated bacillary angiomatosis (BA) was 1.2 cases per 1000 patients [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H14119143"><span class="h1">GENERAL CLINICAL ISSUES</span></p><p class="headingAnchor" id="H3833845892"><span class="h2">Clinical characteristics</span><span class="headingEndMark"> — </span>In people with HIV, clinically evident <em>Bartonella</em> infections occur primarily among those with advanced HIV (eg, CD4 count &lt;100 cells/microL). In one study of 42 patients with HIV with active <em>B. henselae</em> infection, the median CD4 count was 21 cells/microL [<a href="#rid9">9</a>].</p><p>The most common form of bartonellosis in people with HIV is bacillary angiomatosis (BA), which typically presents as cutaneous violaceous lesions. <em>Bartonella</em> infections can also involve internal organs in people with HIV and can produce a broad array of additional manifestations including bacillary peliosis hepatis (infection of the liver), splenitis, osteomyelitis, and bacteremia. Details regarding specific bartonellosis syndromes in people with HIV are found below. (See <a class="local">'Specific syndromes'</a> below.)</p><p>Clinical onset can be gradual with nonspecific symptoms, so the diagnosis is often delayed until several months into the course of illness [<a href="#rid10">10</a>]. With all forms of bartonellosis, patients may or may not have constitutional symptoms such as fever, chills, night sweats, malaise, headache, anorexia, and weight loss.</p><p class="headingAnchor" id="H2169664091"><span class="h2">Diagnostic challenges</span><span class="headingEndMark"> — </span>Bartonellosis in individuals with HIV is often not suspected during the initial presentation. Reasons for missed diagnoses include the substantial variability in presentation between <em>Bartonella</em> syndromes, the nonspecific findings for each syndrome, and the rarity of HIV-related bartonellosis in general (especially in the era of antiretroviral therapy [ART]).</p><p>Definitive diagnosis of bartonellosis in people with HIV requires detection of the organism by polymerase chain reaction (PCR) or culture or visualization of the organism on tissue biopsy. Diagnostic approaches for each specific syndrome in people with HIV are discussed elsewhere. (See <a class="local">'Specific syndromes'</a> below.)</p><p>Serologic testing can be helpful but cannot definitively diagnose or exclude bartonellosis in the absence of other more definitive tests. Furthermore, the coexistence of HIV can complicate the interpretation of <em>Bartonella </em>serologic results:</p><p class="bulletIndent1"><span class="glyph">●</span>A positive serologic result does not always imply active infection, especially in people with HIV who, as described above, have relatively high rates of seropositivity at baseline (see <a class="local">'Seroprevalence'</a> above). Furthermore, data on the serologic response to <em>Bartonella </em>infection in people with HIV are scarce and mostly are derived from studies involving individuals with cat scratch disease [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A negative serologic test does not necessarily rule out the diagnosis, especially in people with HIV with who have a CD4 count less than 200 cells/microL because they may not be able to generate antibody responses at detectable levels (or increased titers over baseline) [<a href="#rid13">13</a>]. One observational study found that nearly 25 percent of people with advanced HIV who had culture-confirmed<em> Bartonella</em> infection never developed a positive <em>Bartonella</em> antibody titer [<a href="#rid14">14</a>].</p><p></p><p>Details on the use and interpretation of PCR, culture, histopathology, and serologic tests for <em>Bartonella</em> are found elsewhere. (See  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a>.)</p><p class="headingAnchor" id="H2573610667"><span class="h2">Rationale for treatment recommendations</span><span class="headingEndMark"> — </span>All people with HIV who are diagnosed with <em>Bartonella</em> infection should receive antibiotic therapy [<a href="#rid10">10,15,16</a>]. No randomized trials have evaluated the optimal treatment regimen for bartonellosis in people with HIV. Data to inform antibiotic selection and duration are limited primarily to case series and small observational studies, and our approach is based on these as well as clinical experience. It is also largely consistent with other expert guidelines [<a href="#rid10">10,15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a><strong> and macrolides as primary treatment options</strong> – Reviews of published case series and case reports have described successful use of <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> or doxycycline, primarily in populations without HIV [<a href="#rid15">15-17</a>]. Other macrolide antibiotics (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> or <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>) have been used successfully as an alternative to erythromycin and may be better tolerated, but there is less published clinical experience with those options [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a>, fluoroquinolones, penicillins, and first-generation cephalosporins have less reliable activity against <em>Bartonella</em> and thus are not recommended [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – Generally, treatment is continued for three months, with the option to extend therapy if complete clinical resolution has not occurred. The optimal duration of treatment for people with HIV has not been established, but relatively long durations are suggested due to the intracellular nature of the organism and the advanced level of immunosuppression among most individuals with HIV who are diagnosed with <em>Bartonella</em> infection.</p><p></p><p>Detailed treatment recommendations for specific <em>Bartonella </em>syndromes are described below. (See <a class="local">'Specific syndromes'</a> below.)</p><p class="headingAnchor" id="H3744357918"><span class="h2">When to initiate antiretroviral therapy</span><span class="headingEndMark"> — </span>In general, ART should be administered to people with HIV who are not receiving ART at the time of <em>Bartonella</em> diagnosis. When selecting a regimen, it is important to assess for drug interactions, particularly if <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> is used. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p>However, the exact timing for when to initiate ART depends on the clinical presentation of <em>Bartonella</em> infection. In persons with HIV who have central nervous system (CNS) or ophthalmic bartonellosis, we agree with guidelines that suggest deferring ART two to four weeks after starting antimicrobial treatment for <em>Bartonella</em> [<a href="#rid10">10</a>]. For patients with other manifestations of <em>Bartonella</em> (eg, skin lesions, endocarditis), we administer ART as soon as possible since restoration of the immune system may augment the response to antimicrobial therapy. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>The rationale for this approach is based upon concern that an immune reconstitution inflammatory syndrome (IRIS) may lead to serious complications related to certain <em>Bartonella</em> infections. Although there are only rare reports describing IRIS with <em>Bartonella</em> infection in persons with HIV [<a href="#rid17">17,20</a>], poor clinical outcomes related to IRIS have been demonstrated in patients with other opportunistic infections that affect the CNS and the eye such as cryptococcosis, cytomegalovirus, and toxoplasmosis. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a> and  <a class="medical medical_review" href="/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'When to initiate antiretroviral therapy'</a> and  <a class="medical medical_review" href="/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis", section on 'CMV immune reconstitution inflammatory syndromes'</a> and  <a class="medical medical_review" href="/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Toxoplasmosis and immune reconstitution syndrome (IRIS)'</a>.)</p><p class="headingAnchor" id="H3325221547"><span class="h1">SPECIFIC SYNDROMES</span><span class="headingEndMark"> — </span>Bartonellosis in people with HIV manifests as several distinct syndromes that sometimes overlap.</p><p class="headingAnchor" id="H2"><span class="h2">Bacillary angiomatosis</span><span class="headingEndMark"> — </span>Bacillary angiomatosis (BA) is characterized by unique vascular lesions that most frequently involve the skin but can affect other organs such as bone, lymph nodes, respiratory tract, and gastrointestinal tract.</p><p class="headingAnchor" id="H3258380967"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Like other bartonellosis syndromes in persons with HIV, BA typically occurs in people with a CD4 count less than 100 cells/microL, and systemic symptoms may or may not occur. (See <a class="local">'Clinical characteristics'</a> above.)</p><p>In addition, BA has unique clinical features that vary depending on the affected organ(s), as detailed in the sections that follow.</p><p class="headingAnchor" id="H2104531598"><span class="h4">Dermatologic manifestations</span><span class="headingEndMark"> — </span>Dermatologic lesions are the most common manifestation of BA.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous lesions</strong> <strong>–</strong> Cutaneous BA may appear as angiomatous vascular lesions that are difficult to diagnose because of variations in appearance [<a href="#rid16">16,21</a>]. The lesions most frequently consist of papular, nodular, pedunculated, or verrucous forms. They typically first develop as small, smooth red-to-purple papules that may subsequently erode, with or without crusting. They can gradually expand into large pedunculated lesions or nodules that can be friable. Lesions may bleed profusely with trauma  (<a class="graphic graphic_picture graphicRef78497 graphicRef82760 graphicRef82759" href="/d/graphic/78497.html" rel="external">picture 1A-C</a>).</p><p></p><p class="bulletIndent1">Infrequently, cutaneous BA lesions have no superficial evidence of vascularity and instead appear as hyperpigmented hyperkeratotic plaques with scaling. Cellulitic plaques sometimes overlie an osteomyelitic bone infection [<a href="#rid1">1,16,22</a>]. (See <a class="local">'Osteomyelitis'</a> below.)</p><p></p><p class="bulletIndent1">Most often, cutaneous lesions in BA are solitary or several in number but rarely may appear in a disseminated version manifested by more than 1000 small lesions [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous lesions</strong> <strong>–</strong> Subcutaneous lesions may develop as deeper tender nodules that have erythematous or normal-appearing overlying skin [<a href="#rid16">16</a>]. These lesions can erode through the cutaneous surface and become superinfected. Less frequently, the lesions develop as an enlarging, deep suppurative ulcer  (<a class="graphic graphic_picture graphicRef82761" href="/d/graphic/82761.html" rel="external">picture 2</a>) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucosal lesions</strong> <strong>–</strong> Oral lesions can occur with or without cutaneous manifestations. Several reports have described lesions on the gingival region, buccal mucosa, oral labial mucosa, hard palate, and posterior pharynx [<a href="#rid24">24</a>]. The mucosal lesions appear as smooth purple papules or plaques that may resemble pyogenic granuloma or Kaposi sarcoma. Rarely, patients may develop a nodular mass of the conjunctiva [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H102776892"><span class="h4">Lymphadenopathy</span><span class="headingEndMark"> — </span>BA can involve single or multiple lymph nodes in people with HIV [<a href="#rid16">16</a>]. Involved lymph nodes may be those that drain either a cutaneous BA lesion or the liver and spleen in cases of liver or spleen involvement. Suppuration and drainage of involved lymph nodes does not typically occur.</p><p class="headingAnchor" id="H5"><span class="h4">Osteomyelitis</span><span class="headingEndMark"> — </span>Bone infection in patients with BA is not uncommon. Although osteomyelitis most often presents in individuals with cutaneous disease, rarely it can develop prior to any other manifestations of BA [<a href="#rid26">26</a>]. Typically, it presents as painful bone lesions, most often involving long bones such as the tibia, fibula, and radius. An overlying cellulitic plaque is often present. Bone radiographs show lytic lesions, and technetium scans show increased uptake at these same sites. Bone lesions can range from focal, well-circumscribed lytic areas to ill-defined areas that show aggressive cortical destruction with notable periosteal reaction.</p><p class="headingAnchor" id="H4288590285"><span class="h4">Other syndromes</span><span class="headingEndMark"> — </span>BA lesions have also been described in the gastrointestinal and respiratory tracts. In gastrointestinal disease, endoscopy reveals raised ulcerated nodules in the stomach and intestines. Respiratory disease manifests as BA lesions in the larynx, trachea, or bronchi [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2174299506"><span class="h3">Diagnostic approach</span><span class="headingEndMark"> — </span>BA should be considered in people with advanced HIV (ie, CD4 &lt;100 cells/microL) who present with angiomatous vascular cutaneous lesions. When dermatologic findings are not present, suspicion for BA may be blunted due to the lack of visible findings, but BA should be considered in persons with HIV and a CD4 count less than 100 cells/microL who have lymphadenopathy, osteomyelitis, or other consistent syndromes without clear etiology. (See <a class="local">'Diagnostic challenges'</a> above.)</p><p>Definitive diagnosis of BA requires a tissue biopsy of an affected organ, usually the skin. Biopsy samples should be sent for histopathology, polymerase chain reaction (PCR) testing, culture, and, if available, Warthin-Starry silver staining. In addition to tissue biopsy, if clinical suspicion is high, we typically send blood samples for culture and PCR. Although sensitivity is lower for blood tests than for tissue samples, a positive blood PCR or culture can help to confirm diagnosis. We also send <em>Bartonella</em> serologic testing, which can help support or diminish a diagnosis of BA but should not be used to make a definitive diagnosis. More details regarding collection and interpretation of these microbiologic tests for <em>Bartonella </em>are found elsewhere. (See <a class="local">'Diagnostic challenges'</a> above and  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a>.)</p><p>In BA, characteristic histologic findings with detection of the organism in biopsied tissue can confirm the diagnosis. Standard hematoxylin and eosin (H&amp;E) staining characteristically shows lobular vascular proliferations composed of rounded vessels lined by variably protuberant plump endothelial cells  (<a class="graphic graphic_picture graphicRef54383" href="/d/graphic/54383.html" rel="external">picture 3</a>) [<a href="#rid27">27,28</a>]. In addition, clusters of neutrophils, neutrophilic debris, and lymphocytes are scattered throughout the lesions, especially around eosinophilic granular aggregates. Warthin-Starry staining may reveal large numbers of small dark-staining bacilli consistent with <em>Bartonella</em>. Further detail regarding histopathology and Warthin-Starry staining for <em>Bartonella </em>syndromes is found elsewhere. (See  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections", section on 'Histopathology'</a>.)</p><p class="headingAnchor" id="H453450816"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>BA lesions have variable appearances, and tissue biopsy not only helps to confirm the diagnosis but also rules out alternative diagnoses that have a similar appearance.</p><p>Cutaneous BA lesions may resemble Kaposi sarcoma, pyogenic granuloma, cherry angioma, dermatofibroma, or hemangioma. The nodular and plaque forms of BA may resemble lesions caused by mycobacteria, tuberculosis, coccidioidomycosis, cryptococcosis, histoplasmosis, or sporotrichosis. Verruga peruana, the cutaneous lesion associated with South American bartonellosis, can resemble cutaneous BA. (See  <a class="medical medical_review" href="/d/html/5516.html" rel="external">"South American bartonellosis: Oroya fever and verruga peruana"</a>.)</p><p>Concomitant disease has been reported in at least one patient who had both cutaneous BA and Kaposi sarcoma that were only differentiated by biopsies of multiple dermatologic lesions [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1616097713"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Treatment of BA depends on the presence of bacteremia and severity of illness.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BA without bacteremia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinically stable patients</strong> <strong>–</strong> Based on numerous case reports, we suggest treatment with oral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily) for individuals with BA who are clinically stable [<a href="#rid16">16</a>]. Oral <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> (500 mg orally four times daily) is also considered a first-line agent, but we prefer doxycycline due to fewer side effects and drug interactions and a more favorable dosing schedule. For patients who are unable to take doxycycline or erythromycin, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg orally once daily) can be used as an alternative. <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">Clarithromycin</a> is also considered an alternative agent, but we prefer azithromycin because it has fewer side effects, fewer drug interactions, better tolerance, and intravenous and oral formulations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Critical infection</strong> <strong>–</strong> For patients with life-threatening infection (eg, hypotension or requiring care in the intensive care unit), we agree with guidelines that suggest parenteral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg intravenously [IV] every 12 hours) plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (300 mg IV every 12 hours) [<a href="#rid10">10</a>]. For patients who are unable to receive doxycycline, we suggest rifampin plus either <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> (500 mg IV every six hours) or <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg IV once daily). The patient can transition from intravenous to oral therapy after becoming clinically stable.</p><p></p><p class="bulletIndent1">Regardless of the severity of illness, the duration of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or macrolide therapy is three months, with the option to extend to longer courses if complete clinical resolution has not occurred. If <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> is used as a second agent, it is typically discontinued after 14 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BA with bacteremia</strong> <strong>–</strong> For patients with bacteremia, we suggest a more aggressive treatment regimen. Details are discussed below. (See <a class="local">'Bacteremia'</a> below.)</p><p></p><p>Additional rationale for treatment choices in HIV-associated <em>Bartonella</em> is discussed elsewhere. (See <a class="local">'Rationale for treatment recommendations'</a> above.)</p><p class="headingAnchor" id="H8"><span class="h2">Bacillary peliosis hepatis and splenitis</span><span class="headingEndMark"> — </span>Peliosis hepatis is a spectrum of liver illnesses with similar pathology that can have infectious or noninfectious etiologies. When peliosis hepatis is caused by <em>Bartonella </em>infection, it is termed "bacillary peliosis hepatis." More information regarding peliosis hepatis syndromes can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/3603.html" rel="external">"Peliosis hepatis"</a>.)</p><p class="headingAnchor" id="H3482479065"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>The clinical presentation of bacillary peliosis hepatis is variable [<a href="#rid29">29</a>]. Splenitis sometimes occurs with bacillary peliosis hepatis, but splenitis in the absence of bacillary peliosis hepatis is rare [<a href="#rid16">16</a>].</p><p>In general, reports suggest that patients often present with abdominal pain with or without systemic symptoms (eg, fever). Physical exam may reveal cutaneous BA lesions, although this is not universal (see <a class="local">'Dermatologic manifestations'</a> above). Hepatomegaly and splenomegaly may be detected on exam. Although rare, patients may present with hypovolemic shock due to hepatic hemorrhage and hemoperitoneum [<a href="#rid30">30</a>].</p><p>Typical laboratory abnormalities include an elevated alkaline phosphatase with or without mild aminotransferase elevation. Some patients have pancytopenia or thrombocytopenia.</p><p>Abdominal computed tomography (CT) typically shows hepatosplenomegaly with hypodense lesions scattered throughout the parenchyma of the liver and spleen [<a href="#rid31">31</a>]. However, other conditions can produce similar CT findings such as lymphoma, disseminated <em>Mycobacterium avium</em> complex, and extrapulmonary <em>Pneumocystis</em> pneumonia. Ultrasound typically shows abnormal lesions that may be hypoechoic, hyperechoic, or heterogenous depending on the stage of illness.</p><p class="headingAnchor" id="H2526732069"><span class="h3">Diagnostic approach</span><span class="headingEndMark"> — </span>In general, bacillary peliosis hepatis and/or splenitis should be considered in people with advanced HIV (eg, CD4 less than 100 cells/microL) and compatible features including abdominal pain, hepatomegaly, elevated alkaline phosphatase, and characteristic findings (ie, hypodense lesions) on abdominal CT or liver lesions on ultrasound.</p><p>To make a definitive diagnosis of bacillary peliosis hepatis and/or splenitis, specific microbiologic testing is necessary. We suggest sending a combination of microbiologic tests including blood samples for PCR testing, culture, and serology. More details regarding these tests and their interpretation are found elsewhere. (See <a class="local">'Diagnostic challenges'</a> above and  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a>.)</p><p>Tissue biopsy is the most definitive method of diagnosis, but liver or spleen biopsy carries an attendant risk of hemorrhage in individuals with peliosis hepatis and splenitis. Thus, a definitive diagnosis of peliosis hepatis or splenitis is often not obtained, and presumptive therapy is initiated based on available supportive data such as serologic tests and radiographic findings. Biopsy should only be considered when the diagnosis remains unclear and the patient is clinically worsening on presumptive therapy. In lieu of liver or spleen biopsy, skin biopsy may provide a definitive diagnosis in individuals with cutaneous lesions consistent with BA.</p><p>If liver biopsy is performed, histopathologic findings typically consist of cystic blood-filled spaces and fibromyxoid stroma that contains a mixture of inflammatory cells, dilated capillaries, and granular purple material. Warthin-Starry staining of these lesions demonstrates findings similar to BA.</p><p>More detailed information on the diagnostic approach and testing for <em>Bartonella </em>and for peliosis hepatis is described elsewhere. (See  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a> and  <a class="medical medical_review" href="/d/html/3603.html" rel="external">"Peliosis hepatis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2976630788"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>If bacillary peliosis hepatis or splenitis is suspected, we suggest parenteral therapy for initial treatment because these infections can have a rapidly progressive course with devastating hemorrhage complications. Treatment suggestions for this syndrome are based on case reports, clinical experience, and expert opinion [<a href="#rid29">29,32,33</a>]. (See <a class="local">'Rationale for treatment recommendations'</a> above.)</p><p>For stable individuals with bacillary peliosis hepatis and/or splenitis, we prefer to start with parenteral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg IV twice daily) or <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> (500 mg IV four times daily). For patients who are unable to take doxycycline or erythromycin, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg IV once daily) is an acceptable alternative. If patients have life-threatening bacillary peliosis hepatis or splenitis (eg, hypotension or requiring care in the intensive care unit), we add <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (300 mg IV every 12 hours) to the regimen as a second agent.</p><p>After clinical improvement, patients can transition to the oral formulation of their parenteral regimen. The total duration of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or macrolide therapy is typically three months, and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (if used) is continued for 14 days.</p><p>For bacteremic patients, treatment recommendations are discussed below. (See <a class="local">'Bacteremia'</a> below.)</p><p class="headingAnchor" id="H2122173326"><span class="h2">Central nervous system infection</span><span class="headingEndMark"> — </span>Central nervous system (CNS) infection is relatively uncommon in patients with HIV.</p><p class="headingAnchor" id="H1229185478"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Case reports have described various CNS syndromes in people with HIV.</p><p>One report described a patient with a 2 cm brain mass that preceded the development of a cutaneous BA lesion [<a href="#rid34">34</a>]. Brain biopsy studies, including Warthin-Starry staining and electron microscopy, showed evidence of typical-appearing <em>Bartonella</em> bacilli. The patient had gradual, but dramatic, clinical and radiographic improvement during a prolonged course of <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>.</p><p>Another report involved a patient with trigeminal neuralgia, low back pain, and spine MRI findings suggestive of vascular defects in L3 and L4 [<a href="#rid35">35</a>]. The patient's lesions resolved with antibiotic therapy.</p><p>Other reports have described aseptic meningitis due to <em>B. henselae</em> in patients with HIV [<a href="#rid36">36,37</a>].</p><p>Early reports suggested dementia and psychiatric symptoms possibly related to <em>Bartonella</em> infection, but a large study using the San Diego HIV Neurobehavioral Research Study database failed to show any correlation between <em>B. henselae</em> serostatus and neurocognitive decline in people with HIV [<a href="#rid7">7,36,38</a>].</p><p class="headingAnchor" id="H3280514110"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Management of CNS infections depends on the presence or absence of bacteremia. Treatment recommendations are based on case reports and experience with other bartonellosis syndromes. (See <a class="local">'Rationale for treatment recommendations'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNS infection without bacteremia</strong> <strong>–</strong> Patients with CNS disease should receive <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally or IV twice daily) for three to four months. Intravenous doxycycline therapy is preferable for initial therapy in hospitalized patients and should be switched to oral therapy once an appropriate clinical response occurs.</p><p></p><p class="bulletIndent1">For severe CNS disease, we add <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (300 mg orally or IV twice daily) as a second agent for the first 14 days of therapy [<a href="#rid10">10</a>]. Several case reports in persons without HIV have described combination therapy with rifampin to treat patients with neurologic involvement, including retinitis [<a href="#rid39">39-41</a>]. However, we typically do not add rifampin for nonsevere CNS disease because data to support rifampin in people with HIV are lacking.</p><p></p><p class="bulletIndent1">The macrolides are likely inferior to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for the treatment of CNS disease due to lower cerebrospinal fluid penetration. However, they could be considered as an alternative for individuals unable to take doxycycline [<a href="#rid15">15,42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNS infection with bacteremia</strong> <strong>–</strong> For all patients with bacteremia and CNS infection, we suggest <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg IV twice daily) for three to four months plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (300 mg orally or IV twice daily) for 14 days.</p><p></p><p class="headingAnchor" id="H2152247581"><span class="h2">Unexplained fever</span><span class="headingEndMark"> — </span><em>Bartonella</em> should be considered in the differential diagnosis of unexplained fever in individuals with CD4 counts below 100 cells/microL [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 382 patients from San Francisco with unexplained fever (95 percent of whom were infected with HIV), 12 (3 percent) had confirmed <em>Bartonella</em> infection by culture or PCR of blood or tissue [<a href="#rid14">14</a>]. An additional 56 (15 percent) had only positive serology, 21 of whom had serologic titers ≥1:512. Most of the patients with evidence of <em>Bartonella</em> infection had advanced HIV disease and a CD4 count less than 100 cells/microL. It is not clear that <em>Bartonella</em>, when isolated, was the cause of unexplained fever in these patients since no information on therapy and follow-up was provided. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, extended-incubation blood cultures identified two cases of <em>Bartonella</em> infection among 45 AIDS patients who had unexplained fever [<a href="#rid44">44</a>].</p><p></p><p>When bartonellosis is suspected for unexplained fever in people with HIV, microbiologic testing should include blood samples for serology, PCR testing, and culture. Details regarding these tests and their interpretation are found elsewhere. (See <a class="local">'Diagnostic challenges'</a> above and  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a>.)</p><p>Abnormalities on physical examination or lab work should prompt further evaluation for one of the organ-specific bartonellosis syndromes. Details regarding specific syndromes are found elsewhere. (See <a class="local">'Specific syndromes'</a> above.)</p><p>For treatment of unexplained fever due to bartonellosis with no evidence of organ-specific disease, we suggest management similar to treatment for BA, preferably with oral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice daily for three months.</p><p class="headingAnchor" id="H9"><span class="h2">Bacteremia</span><span class="headingEndMark"> — </span>Bacteremia is sometimes detected in individuals with BA, bacillary peliosis hepatis, or splenitis. It can also be discovered during workup for unexplained fever or other systemic symptoms.</p><p>The diagnosis of bacteremia is established by positive blood culture or blood PCR results. However, bacteremia is probably significantly underdiagnosed because isolation of the <em>Bartonella</em> organisms in culture remains difficult, and PCR testing of blood is not routinely ordered and has suboptimal sensitivity. More information on diagnostic testing for <em>Bartonella </em>is found elsewhere. (See  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Whenever <em>Bartonella </em>bacteremia is detected, careful physical examination and basic lab work, including liver function tests, should be performed, which may prompt further evaluation of one of the organ-specific bartonellosis syndromes. (See <a class="local">'Specific syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All individuals with bacteremia should have workup for endocarditis, including echocardiogram. Detailed information can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/2145.html" rel="external">"Endocarditis caused by Bartonella"</a>.)</p><p></p><p>For patients with bacteremia, we suggest treatment with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally or IV twice daily) for three months. We typically add either intravenous <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (3 mg/kg/day given once daily) or <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (300 mg twice daily for the first 14 days of treatment), although some experts would not add a second agent [<a href="#rid45">45</a>]. Gentamicin should not be used in persons with baseline renal insufficiency and should be discontinued if renal insufficiency develops. The gentamicin dose should be adjusted, if needed, to achieve trough serum concentrations of &lt;1 mcg/mL. (See  <a class="medical medical_review" href="/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p>There are no data regarding treatment regimens for <em>Bartonella </em>bacteremia in individuals with HIV. Case series and trials in patients without HIV suggest that combination therapy that includes a 14-day course of <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> is effective for the treatment of bacteremia or endocarditis [<a href="#rid45">45,46</a>]. The potential benefit of using gentamicin or <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> as a second drug in the treatment of bacteremia should be weighed against the potential nephrotoxicity with gentamicin and the potential problematic drug interactions between rifampin and other medications, particularly HIV antiretroviral medications. (See <a class="local">'Rationale for treatment recommendations'</a> above.)</p><p class="headingAnchor" id="H1837041796"><span class="h2">Endocarditis</span><span class="headingEndMark"> — </span><em>Bartonella </em>is a known cause of culture-negative endocarditis, and <em>Bartonella</em>-associated endocarditis has been reported among individuals with HIV [<a href="#rid47">47</a>].</p><p>The treatment of <em>Bartonella</em> endocarditis in people with HIV is the same as for patients without HIV. (See  <a class="medical medical_review" href="/d/html/2145.html" rel="external">"Endocarditis caused by Bartonella", section on 'Antimicrobial therapy'</a>.)</p><p>A detailed discussion of <em>Bartonella</em> endocarditis is found elsewhere. (See  <a class="medical medical_review" href="/d/html/2145.html" rel="external">"Endocarditis caused by Bartonella"</a>.)</p><p class="headingAnchor" id="H3666571818"><span class="h1">PREGNANT INDIVIDUALS</span><span class="headingEndMark"> — </span>Based on a limited number of individual case reports, the clinical features of bacillary angiomatosis (BA) in pregnant individuals appear to be similar to those in nonpregnant individuals [<a href="#rid48">48,49</a>]. Data regarding bartonellosis syndromes other than BA in pregnant people with HIV are scarce. However, cases of maternal death have been reported in pregnant individuals without HIV who develop idiopathic peliosis hepatitis not due to <em>Bartonella </em>[<a href="#rid50">50-52</a>]<em>.</em></p><p>For treatment of bartonellosis in pregnant individuals, we agree with guidelines that recommend <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> or an alternative macrolide [<a href="#rid10">10</a>]. For syndromes for which combination therapy is indicated, we suggest a macrolide plus either <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> depending on the syndrome. The duration of therapy in pregnancy is identical to the duration recommended based on each syndrome. (See <a class="local">'Specific syndromes'</a> above.)</p><p><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is not recommended for pregnant individuals due to increased risk of hepatotoxicity and the accumulation of <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> in fetal teeth and bones, which can cause permanent staining of fetal teeth. Third-generation cephalosporins, such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, may be effective, but data are limited. First- and second-generation cephalosporins are not recommended due to lack of efficacy against <em>Bartonella </em>[<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2797634699"><span class="h1">FOLLOW-UP AFTER TREATMENT</span></p><p class="headingAnchor" id="H3260855463"><span class="h2">Monitoring response to therapy</span><span class="headingEndMark"> — </span>Patients should be monitored closely during therapy for resolution of signs and symptoms including fever and cutaneous or other bacillary angiomatosis (BA) lesions.</p><p>For patients with bacillary peliosis hepatis, laboratory abnormalities (eg, alkaline phosphatase, thrombocytopenia) should improve during therapy. We recommend repeating abdominal imaging after four to six weeks of treatment.</p><p>We typically do not monitor IgG levels to follow treatment response because changes in levels (or lack thereof) may be difficult to interpret and there is a lack of data to support this approach. However, some experts recommend following IgG levels based on a case report of a patient with aortitis whose IgG levels decreased on therapy, but it was unclear whether treatment led to the falling titer versus immune reconstitution from the initiation of antiretroviral therapy (ART) during treatment [<a href="#rid10">10,53</a>].</p><p class="headingAnchor" id="H224883062"><span class="h2">Refractory infection</span><span class="headingEndMark"> — </span>There are no studies that have addressed the optimal approach for patients who fail to respond to therapy. In such patients, we add <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> if it was not used in the original treatment regimen. For patients with peliosis hepatis, we also consider adding <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> for 14 days. In addition to revising antimicrobial therapy, ART should be optimized to promote immune reconstitution.</p><p class="headingAnchor" id="H611711470"><span class="h2">Recurrent infection</span><span class="headingEndMark"> — </span>For patients who have a relapse of disease after receiving at least three months of therapy, we agree with guideline recommendations for an additional full course of treatment followed by long-term suppression with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or a macrolide at the same doses used for treatment [<a href="#rid10">10</a>]. ART should be optimized to promote immune reconstitution. Suppressive therapy can be discontinued after at least three months of therapy and once the CD4 count has been &gt;200 cells/microL for at least six months.</p><p class="headingAnchor" id="H693656577"><span class="h1">COMPLICATIONS</span></p><p class="headingAnchor" id="H951509200"><span class="h2">Hemophagocytic lymphohistiocytosis</span><span class="headingEndMark"> — </span><em>B. henselae</em> has been associated with hemophagocytic lymphohistiocytosis (HLH). In one case report, a 69-year-old man with HIV and <em>B</em>. <em>henselae</em>-associated HLH was successfully treated with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, and corticosteroids [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p class="headingAnchor" id="H2141068530"><span class="h2">Immune reconstitution inflammatory syndrome</span><span class="headingEndMark"> — </span>On rare occasion, people with HIV and <em>Bartonella</em> infection can develop significant worsening of <em>Bartonella</em> infection after initiating antiretroviral therapy (ART) [<a href="#rid17">17,20</a>]. This immune reconstitution inflammatory syndrome (IRIS) occurs as a consequence of rapid up-regulation in the immune system and, if severe, may require corticosteroid therapy. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>The timing of when to initiate ART in people with HIV and bartonellosis is described above. (See <a class="local">'When to initiate antiretroviral therapy'</a> above.)</p><p class="headingAnchor" id="H4241728483"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention of bartonellosis in people with HIV primarily focuses on behavioral modifications; the role for antimicrobial prophylaxis is limited.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral modifications</strong> – We counsel patients, especially those with a CD4 count &lt;200 cells/microL, on how to decrease the risk of developing <em>Bartonella</em>. Since the development of <em>B. henselae</em> infection is related to cat exposure, we advise the following for our patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid cat scratches</p><p class="bulletIndent2"><span class="glyph">•</span>Control flea infestations</p><p class="bulletIndent2"><span class="glyph">•</span>Avoid acquisition of an unhealthy cat or a cat that is younger than one year old</p><p></p><p class="bulletIndent1">People who are homeless or intermittently housed should receive the following to reduce the risk of <em>B. quintana</em> exposure:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Education regarding prevention of lice infestation</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of lice infestation to minimize their risk of developing systemic <em>B. quintana</em> infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for primary prophylaxis</strong> – We agree with guidelines that primary prophylactic antimicrobials are not recommended to prevent <em>Bartonella</em> infection in people with HIV [<a href="#rid10">10</a>]. A single retrospective, case-control study reported a protective effect against <em>Bartonella</em> infection in patients receiving a macrolide or a rifamycin for prophylaxis against disseminated <em>M. avium</em> complex [<a href="#rid4">4</a>]. Despite this finding, prophylactic therapy specific for <em>Bartonella</em> infection is not recommended given the low incidence of <em>Bartonella</em> infection in people with HIV and the lack of prospective data [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for secondary prophylaxis</strong> – Secondary prophylaxis is only recommended in people with HIV who have experienced a recurrence of bartonellosis. Detailed recommendations are found above. (See <a class="local">'Recurrent infection'</a> above.)</p><p></p><p class="headingAnchor" id="H3121711153"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H14119273"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> <strong>–</strong> Among people with HIV, symptomatic <em>Bartonella</em> infections occur primarily in those whose CD4 count is &lt;100 cells/microL. (See <a class="local">'Clinical characteristics'</a> above.)</p><p></p><p class="bulletIndent1"><em>Bartonella henselae</em> and <em>Bartonella quintana</em> are the two primary causes. Patients with <em>B. henselae</em> infection usually have a link to cats, whereas <em>B. quintana</em> predominantly infects people who are homeless and have head or body lice exposure. (See <a class="local">'Microbiology'</a> above and <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> <strong>–</strong> Definitive diagnosis in people with HIV requires detection of the organism by polymerase chain reaction (PCR) or culture or visualization of the organism on tissue biopsy. Serologic testing can be helpful but cannot definitively diagnose or exclude bartonellosis. The specific clinical syndrome determines the most appropriate tests to order. (See <a class="local">'Diagnostic challenges'</a> above and <a class="local">'Specific syndromes'</a> above and  <a class="medical medical_review" href="/d/html/16504.html" rel="external">"Microbiologic diagnosis of Bartonella infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical syndromes</strong> <strong>–</strong> Bartonellosis in people with HIV manifests as several distinct syndromes that sometimes overlap. Constitutional symptoms may occur including fever, chills, malaise, headache, anorexia, and weight loss. (See <a class="local">'Clinical characteristics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacillary angiomatosis (BA)</strong> <strong>–</strong> This syndrome is characterized by unique vascular lesions that most frequently involve the skin but can affect other organs. (See <a class="local">'Bacillary angiomatosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Clinical manifestations</strong> <strong>–</strong> Cutaneous lesions usually appear as angiomatous vascular lesions that are papular, nodular, pedunculated, or verrucous. They may resemble Kaposi sarcoma, pyogenic granuloma, cherry angioma, dermatofibroma, hemangioma, or other cutaneous lesions. If other organs are involved, manifestations may include lymphadenopathy, bone pain from osteomyelitis, or respiratory or gastrointestinal symptoms. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Diagnosis</strong> <strong>–</strong> Definitive diagnosis of BA requires a tissue biopsy of an affected organ, usually the skin. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Treatment</strong> <strong>–</strong> For clinically stable patients without bacteremia, we suggest <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily) rather than a macrolide (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For critically ill patients, we suggest doxycycline (100 mg intravenously [IV] every 12 hours) plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (300 mg IV every 12 hours) rather than monotherapy with doxycycline (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The typical duration of therapy is three months for doxycycline and 14 days for rifampin. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacillary peliosis hepatis and splenitis</strong> <strong>–</strong> This syndrome is characterized by vascular lesions in the liver and/or spleen. Patients often present with fever, weight loss, hepatosplenomegaly, elevated alkaline phosphatase, and hypodense lesions on abdominal CT. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2">Diagnosis is usually made based on clinical features and imaging, coupled with blood samples for PCR testing, culture, and serology. Tissue biopsy is usually not performed due to risk of hemorrhage. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent2">For treatment, we suggest parenteral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg IV twice daily) or <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> (500 mg IV four times daily) as opposed to oral therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Transition to oral therapy is appropriate once clinical improvement has occurred, and the duration is typically three months. For severely ill patients, we add <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (300 mg IV every 12 hours) as a second agent for 14 days. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other syndromes</strong> <strong>–</strong> Other clinical syndromes and suggested treatment regimens in people with HIV are discussed in the text (eg, central nervous system [CNS] infection, bacteremia, endocarditis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> <strong>–</strong> People with HIV and a CD4 count &lt;200 cells/microL should avoid cat scratches, unhealthy cats, and cats younger than one year old. Lice infestations should be prevented and rapidly treated, especially in individuals who are homeless. There is generally no role for primary prophylaxis with antibiotics. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H3514553159"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Koehler JE, Quinn FD, Berger TG, et al. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992; 327:1625.</a></li><li><a class="nounderline abstract_t">Cotell SL, Noskin GA. Bacillary angiomatosis. Clinical and histologic features, diagnosis, and treatment. Arch Intern Med 1994; 154:524.</a></li><li><a class="nounderline abstract_t">Parte AC, Sardà Carbasse J, Meier-Kolthoff JP, et al. List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. Int J Syst Evol Microbiol 2020; 70:5607.</a></li><li><a class="nounderline abstract_t">Koehler JE, Sanchez MA, Garrido CS, et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med 1997; 337:1876.</a></li><li><a class="nounderline abstract_t">Blanco JR, Oteo JA, Martínez V, et al. [Seroepidemiology of Bartonella henselae infection in HIV-infected patients]. Enferm Infecc Microbiol Clin 1999; 17:434.</a></li><li><a class="nounderline abstract_t">Pape M, Kollaras P, Mandraveli K, et al. Occurrence of Bartonella henselae and Bartonella quintana among human immunodeficiency virus-infected patients. Ann N Y Acad Sci 2005; 1063:299.</a></li><li><a class="nounderline abstract_t">Wallace MR, Persing DH, McCutchan JA, et al. Bartonella henselae serostatus is not correlated with neurocognitive decline in HIV infection. Scand J Infect Dis 2001; 33:593.</a></li><li><a class="nounderline abstract_t">Plettenberg A, Lorenzen T, Burtsche BT, et al. Bacillary angiomatosis in HIV-infected patients--an epidemiological and clinical study. Dermatology 2000; 201:326.</a></li><li><a class="nounderline abstract_t">Mohle-Boetani JC, Koehler JE, Berger TG, et al. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Clin Infect Dis 1996; 22:794.</a></li><li class="breakAll">Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on February 18, 2022).</li><li><a class="nounderline abstract_t">Regnery RL, Olson JG, Perkins BA, Bibb W. Serological response to "Rochalimaea henselae" antigen in suspected cat-scratch disease. Lancet 1992; 339:1443.</a></li><li><a class="nounderline abstract_t">Zangwill KM, Hamilton DH, Perkins BA, et al. Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test. N Engl J Med 1993; 329:8.</a></li><li><a class="nounderline abstract_t">Comer JA, Flynn C, Regnery RL, et al. Antibodies to Bartonella species in inner-city intravenous drug users in Baltimore, Md. Arch Intern Med 1996; 156:2491.</a></li><li><a class="nounderline abstract_t">Koehler JE, Sanchez MA, Tye S, et al. Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever. Clin Infect Dis 2003; 37:559.</a></li><li><a class="nounderline abstract_t">Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921.</a></li><li><a class="nounderline abstract_t">Koehler JE, Tappero JW. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17:612.</a></li><li><a class="nounderline abstract_t">DallaPiazza M, Akiyama MJ. The First Report of Bartonella quintana Immune Reconstitution Inflammatory Syndrome Complicated by Jarisch-Herxheimer Reaction. J Int Assoc Provid AIDS Care 2017; 16:321.</a></li><li><a class="nounderline abstract_t">Guerra LG, Neira CJ, Boman D, et al. Rapid response of AIDS-related bacillary angiomatosis to azithromycin. Clin Infect Dis 1993; 17:264.</a></li><li><a class="nounderline abstract_t">Gadila SKG, Embers ME. Antibiotic Susceptibility of Bartonella Grown in Different Culture Conditions. Pathogens 2021; 10.</a></li><li><a class="nounderline abstract_t">Murillo O, Mimbrera D, Petit A, et al. Fatal bacillary angiomatosis mimicking an infiltrative vascular tumour in the immune restoration phase of an HIV-infected patient. Antivir Ther 2012; 17:405.</a></li><li><a class="nounderline abstract_t">Tappero JW, Perkins BA, Wenger JD, Berger TG. Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin Microbiol Rev 1995; 8:440.</a></li><li><a class="nounderline abstract_t">Webster GF, Cockerell CJ, Friedman-Kien AE. The clinical spectrum of bacillary angiomatosis. Br J Dermatol 1992; 126:535.</a></li><li><a class="nounderline abstract_t">Carrascosa JM, Ribera M, Bielsa I, et al. Bacillary angiomatosis presenting as a malleolar ulcer. Arch Dermatol 1995; 131:963.</a></li><li><a class="nounderline abstract_t">Monteil RA, Michiels JF, Hofman P, et al. Histological and ultrastructural study of one case of oral bacillary angiomatosis in HIV disease and review of the literature. Eur J Cancer B Oral Oncol 1994; 30B:65.</a></li><li><a class="nounderline abstract_t">Lee WR, Chawla JC, Reid R. Bacillary angiomatosis of the conjunctiva. Am J Ophthalmol 1994; 118:152.</a></li><li><a class="nounderline abstract_t">Baron AL, Steinbach LS, LeBoit PE, et al. Osteolytic lesions and bacillary angiomatosis in HIV infection: radiologic differentiation from AIDS-related Kaposi sarcoma. Radiology 1990; 177:77.</a></li><li><a class="nounderline abstract_t">LeBoit PE, Berger TG, Egbert BM, et al. Bacillary angiomatosis. The histopathology and differential diagnosis of a pseudoneoplastic infection in patients with human immunodeficiency virus disease. Am J Surg Pathol 1989; 13:909.</a></li><li><a class="nounderline abstract_t">LeBoit PE, Berger TG, Egbert BM, et al. Epithelioid haemangioma-like vascular proliferation in AIDS: manifestation of cat scratch disease bacillus infection? Lancet 1988; 1:960.</a></li><li><a class="nounderline abstract_t">Perkocha LA, Geaghan SM, Yen TS, et al. Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. N Engl J Med 1990; 323:1581.</a></li><li><a class="nounderline abstract_t">Lozano F, Corzo JE, León EM, et al. Massive hemoperitoneum: a new manifestation of bacillary peliosis in human immunodeficiency virus infection. Clin Infect Dis 1999; 28:911.</a></li><li><a class="nounderline abstract_t">Iannaccone R, Federle MP, Brancatelli G, et al. Peliosis hepatis: spectrum of imaging findings. AJR Am J Roentgenol 2006; 187:W43.</a></li><li><a class="nounderline abstract_t">Kemper CA, Lombard CM, Deresinski SC, Tompkins LS. Visceral bacillary epithelioid angiomatosis: possible manifestations of disseminated cat scratch disease in the immunocompromised host: a report of two cases. Am J Med 1990; 89:216.</a></li><li><a class="nounderline abstract_t">Tappero JW, Koehler JE, Berger TG, et al. Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med 1993; 118:363.</a></li><li><a class="nounderline abstract_t">Spach DH, Panther LA, Thorning DR, et al. Intracerebral bacillary angiomatosis in a patient infected with human immunodeficiency virus. Ann Intern Med 1992; 116:740.</a></li><li><a class="nounderline abstract_t">Harris PJ. Intracerebral bacillary angiomatosis in HIV. Ann Intern Med 1992; 117:795.</a></li><li><a class="nounderline abstract_t">Marra CM. Neurologic complications of Bartonella henselae infection. Curr Opin Neurol 1995; 8:164.</a></li><li><a class="nounderline abstract_t">Wong MT, Dolan MJ, Lattuada CP Jr, et al. Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella (Rochalimaea) henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1. Clin Infect Dis 1995; 21:352.</a></li><li><a class="nounderline abstract_t">Baker J, Ruiz-Rodriguez R, Whitfeld M, et al. Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection. J Clin Psychiatry 1995; 56:161.</a></li><li><a class="nounderline abstract_t">Pham G, Dermarkarian CR, Tran J, Shah VS. Pediatric Bartonella henselae neuroretinitis masking co-infections. Am J Ophthalmol Case Rep 2022; 25:101272.</a></li><li><a class="nounderline abstract_t">Rissardo JP, Caprara ALF. Transverse Myelitis and Guillain-Barré Syndrome Overlap Secondary to Bartonella henselae: Case Report. Prague Med Rep 2019; 120:131.</a></li><li><a class="nounderline abstract_t">Samarkos M, Antoniadou V, Vaiopoulos AG, Psichogiou M. Encephalopathy in an adult with cat-scratch disease. BMJ Case Rep 2018; 2018.</a></li><li class="breakAll">Erythromycin - Drug summary. PDR - Prescriber's digital reference. https://www.pdr.net/drug-summary/Ery-Tab-erythromycin-1706. (Accessed on June 20, 2022).</li><li><a class="nounderline abstract_t">Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 1996; 40:825.</a></li><li><a class="nounderline abstract_t">Dougherty MJ, Spach DH, Larson AM, et al. Evaluation of an extended blood culture protocol to isolate fastidious organisms from patients with AIDS. J Clin Microbiol 1996; 34:2444.</a></li><li><a class="nounderline abstract_t">Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother 2003; 47:2204.</a></li><li><a class="nounderline abstract_t">Raoult D, Fournier PE, Vandenesch F, et al. Outcome and treatment of Bartonella endocarditis. Arch Intern Med 2003; 163:226.</a></li><li><a class="nounderline abstract_t">Spach DH, Callis KP, Paauw DS, et al. Endocarditis caused by Rochalimaea quintana in a patient infected with human immunodeficiency virus. J Clin Microbiol 1993; 31:692.</a></li><li><a class="nounderline abstract_t">Riley LE, Tuomala RE. Bacillary angiomatosis in a pregnant patient with acquired immunodeficiency syndrome. Obstet Gynecol 1992; 79:818.</a></li><li><a class="nounderline abstract_t">Bellissimo-Rodrigues F, da Fonseca BA, Martinez R. Bacillary angiomatosis in a pregnant woman. Int J Gynaecol Obstet 2010; 111:85.</a></li><li><a class="nounderline abstract_t">Cimbanassi S, Aseni P, Mariani A, et al. Spontaneous hepatic rupture during pregnancy in a patient with peliosis hepatis. Ann Hepatol 2015; 14:553.</a></li><li><a class="nounderline abstract_t">Butt MO, Luck NH, Hassan SM, et al. Peliosis Hepatis Complicating Pregnancy: A Rare Entity. J Transl Int Med 2017; 5:132.</a></li><li><a class="nounderline abstract_t">Grønlykke L, Tarp B, Dutoit SH, Wilkens R. Peliosis hepatis: a complicating finding in a case of biliary colic. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Lee SA, Plett SK, Luetkemeyer AF, et al. Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification. J Clin Microbiol 2015; 53:2773.</a></li><li><a class="nounderline abstract_t">Le Joncour A, Bidegain F, Ziol M, et al. Hemophagocytic Lymphohistiocytosis Associated With Bartonella henselae Infection in an HIV-Infected Patient. Clin Infect Dis 2016; 62:804.</a></li></ol></div><div id="topicVersionRevision">Topic 5512 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1435899" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8122945" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bacillary angiomatosis. Clinical and histologic features, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32701423" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9407154" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614075" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : [Seroepidemiology of Bartonella henselae infection in HIV-infected patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481530" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Occurrence of Bartonella henselae and Bartonella quintana among human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11525353" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bartonella henselae serostatus is not correlated with neurocognitive decline in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11146343" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bacillary angiomatosis in HIV-infected patients--an epidemiological and clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722933" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722933" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351130" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serological response to "Rochalimaea henselae" antigen in suspected cat-scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8505963" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8944742" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibodies to Bartonella species in inner-city intravenous drug users in Baltimore, Md.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12905141" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15155180" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recommendations for treatment of human infections caused by Bartonella species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8268340" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28393665" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The First Report of Bartonella quintana Immune Reconstitution Inflammatory Syndrome Complicated by Jarisch-Herxheimer Reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399879" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Rapid response of AIDS-related bacillary angiomatosis to azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34201011" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibiotic Susceptibility of Bartonella Grown in Different Culture Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22293094" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fatal bacillary angiomatosis mimicking an infiltrative vascular tumour in the immune restoration phase of an HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7553576" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1610703" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The clinical spectrum of bacillary angiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7632077" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bacillary angiomatosis presenting as a malleolar ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135977" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Histological and ultrastructural study of one case of oral bacillary angiomatosis in HIV disease and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053460" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bacillary angiomatosis of the conjunctiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2399342" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Osteolytic lesions and bacillary angiomatosis in HIV infection: radiologic differentiation from AIDS-related Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2802010" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bacillary angiomatosis. The histopathology and differential diagnosis of a pseudoneoplastic infection in patients with human immunodeficiency virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2896827" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epithelioid haemangioma-like vascular proliferation in AIDS: manifestation of cat scratch disease bacillus infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2233946" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10825061" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Massive hemoperitoneum: a new manifestation of bacillary peliosis in human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794138" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Peliosis hepatis: spectrum of imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2382668" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Visceral bacillary epithelioid angiomatosis: possible manifestations of disseminated cat scratch disease in the immunocompromised host: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8430982" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bacillary angiomatosis and bacillary splenitis in immunocompetent adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558347" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intracerebral bacillary angiomatosis in a patient infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416588" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intracerebral bacillary angiomatosis in HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7551113" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neurologic complications of Bartonella henselae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562744" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella (Rochalimaea) henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713855" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35112018" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pediatric Bartonella henselae neuroretinitis masking co-infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31935348" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transverse Myelitis and Guillain-BarréSyndrome Overlap Secondary to Bartonella henselae: Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507029" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Encephalopathy in an adult with cat-scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507029" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Encephalopathy in an adult with cat-scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8851625" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880497" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evaluation of an extended blood culture protocol to isolate fastidious organisms from patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821469" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12546614" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcome and treatment of Bartonella endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8458964" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Endocarditis caused by Rochalimaea quintana in a patient infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1565376" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Bacillary angiomatosis in a pregnant patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650456" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Bacillary angiomatosis in a pregnant woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26019044" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Spontaneous hepatic rupture during pregnancy in a patient with peliosis hepatis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28721347" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Peliosis Hepatis Complicating Pregnancy: A Rare Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24072833" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Peliosis hepatis: a complicating finding in a case of biliary colic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063867" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646679" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hemophagocytic Lymphohistiocytosis Associated With Bartonella henselae Infection in an HIV-Infected Patient.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
